A pair of studies published this week present an analysis of a real, large-scale testing pooling effort as well as analyses of how to further improve such strategies.
Emerging technologies included biosensors, host response tests using different types of biomarkers, and new ways to make and develop antigen, antibody, and PCR tests.
Wyss Institute said iQ Group Global will integrate its affinity-based technology with a biosensor platform that includes organic thin-film transistors to enhance electrical signals.
Semi-quantitative SARS-CoV-2 serology tests enable users to measure levels of neutralizing antibodies, but tests need to be more comparable across manufacturers, Siemens said.
The company licensed nasopharyngeal swab and toehold switch molecular detection technologies from the Wyss Institute to develop SARS-CoV-2 diagnostics.
